{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:18:08Z","timestamp":1649157488166},"reference-count":88,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.lpm.2011.06.022","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T19:18:57Z","timestamp":1314904737000},"page":"1065-1073","source":"Crossref","is-referenced-by-count":0,"title":["Ralentir la progression de l\u2019insuffisance r\u00e9nale chronique\u00a0: espoirs et d\u00e9ceptions. La r\u00e9paration vasculaire du rein chronique"],"prefix":"10.1016","volume":"40","author":[{"given":"Jean-Jacques","family":"Boffa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Mihout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2011.06.022_bib0005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0010","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2011.06.022_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/path.2769","article-title":"Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-\u03b21\u00a0synthesis","volume":"223","author":"Mihout","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.jrn.2010.05.002","article-title":"Indoxyl sulfate is a nephro-vascular toxin","volume":"20","author":"Niwa","year":"2010","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.lpm.2011.06.022_bib0025","first-page":"1089","article-title":"Late referral to maintenance dialysis: detrimental consequences","volume":"8","author":"Jungers","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2011.06.022_bib0030","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/ndt\/gfl198","article-title":"Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease","volume":"21","author":"Jones","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2011.06.022_bib0035","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11255-008-9360-9","article-title":"Improvement in eGFR in patients with chronic kidney disease attending a nephrology clinic","volume":"40","author":"Taskapan","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0040","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2011.06.022_bib0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0050","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.06.022_bib0055","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0060","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2\u00a0diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2\u00a0diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0075","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","article-title":"Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study","volume":"16","author":"Schmieder","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0080","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2\u00a0diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","article-title":"The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study","volume":"142","author":"Sarnak","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0090","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0100","unstructured":"Anaes. Moyens th\u00e9rapeutiques pour ralentir la progression de l\u2019insuffisance r\u00e9nale chronique chez l\u2019adulte. Recommandations septembre 2004."},{"key":"10.1016\/j.lpm.2011.06.022_bib0105","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/01.ASN.0000060574.38107.3B","article-title":"Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases","volume":"14","author":"Boffa","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0110","doi-asserted-by":"crossref","first-page":"e6721","DOI":"10.1371\/journal.pone.0006721","article-title":"Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin","volume":"4","author":"Huby","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2011.06.022_bib0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.ajkd.2008.03.008","article-title":"Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression","volume":"52","author":"Catapano","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.06.022_bib0120","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0125","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1681\/ASN.2004060505","article-title":"Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents","volume":"16","author":"Esnault","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.06.022_bib0135","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2\u00a0diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0140","doi-asserted-by":"crossref","unstructured":"Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011.","DOI":"10.1038\/ki.2011.48"},{"key":"10.1016\/j.lpm.2011.06.022_bib0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary aldosteronism from an analysis of 145\u00a0cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am J Surg"},{"key":"10.1016\/j.lpm.2011.06.022_bib0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0155","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0160","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2\u00a0diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0165","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0170","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2\u00a0diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.lpm.2011.06.022_bib0175","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0180","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0185","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0190","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0195","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/hr.2010.46","volume":"33","author":"Ando","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.lpm.2011.06.022_bib0200","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0205","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.06.022_bib0210","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1172\/JCI2132","article-title":"Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin","volume":"101","author":"Chatziantoniou","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2011.06.022_bib0215","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.HYP.37.2.490","article-title":"Regression of renal vascular fibrosis by endothelin receptor antagonism","volume":"37","author":"Boffa","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2011.06.022_bib0220","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1681\/ASN.V12122572","article-title":"Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage","volume":"12","author":"Amann","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0225","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes","volume":"297","author":"Gagliardini","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0230","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0235","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0240","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0245","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1681\/ASN.2007101065","article-title":"Extended prognostic value of urinary albumin excretion for cardiovascular events","volume":"19","author":"Brantsma","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0250","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1172\/JCI112020","article-title":"Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3","volume":"76","author":"Nath","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2011.06.022_bib0255","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.ajkd.2009.02.014","article-title":"Serum bicarbonate levels and the progression of kidney disease: a cohort study","volume":"54","author":"Shah","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.06.022_bib0260","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"de Brito-Ashurst","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0265","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ki.2010.129","article-title":"Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy","volume":"78","author":"Mahajan","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2009.519","article-title":"Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR","volume":"77","author":"Phisitkul","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0275","doi-asserted-by":"crossref","first-page":"F830","DOI":"10.1152\/ajprenal.00587.2010","article-title":"Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone","volume":"300","author":"Wesson","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0280","first-page":"S1","article-title":"Clinical practice guidelines for nutrition in chronic renal failure","volume":"35","author":"K\/DOQI National Kidney Foundation","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.06.022_bib0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats","volume":"67","author":"S\u00e1nchez-Lozada","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0290","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","article-title":"Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971\u20131992. National Health and Nutrition Examination Survey","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2011.06.022_bib0295","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/archinte.159.15.1785","article-title":"Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study","volume":"159","author":"Culleton","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0300","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0305","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0310","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","article-title":"Uric acid and long-term outcomes in CKD","volume":"53","author":"Madero","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.06.022_bib0315","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","article-title":"Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions","volume":"39","author":"Kanbay","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0320","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.06.022_bib0325","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0330","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.lpm.2011.06.022_bib0335","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0340","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1681\/ASN.2006091028","article-title":"Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats","volume":"18","author":"Mizobuchi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0345","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1681\/ASN.2006050520","article-title":"Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy","volume":"17","author":"Tan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0350","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.ajkd.2007.12.038","article-title":"Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial","volume":"51","author":"Szeto","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.06.022_bib0355","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","article-title":"Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial","volume":"54","author":"Fishbane","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.06.022_bib0360","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2\u00a0diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.06.022_bib0365","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.lpm.2007.04.033","article-title":"Strategies to reverse fibrotic lesions of the kidney","volume":"36","author":"Boffa","year":"2007","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0370","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/360361a0","article-title":"Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease","volume":"360","author":"Border","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2011.06.022_bib0375","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1172\/JCI200319270","article-title":"Targeted disruption of TGF-beta1\/Smad3\u00a0signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction","volume":"12","author":"Sato","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2011.06.022_bib0380","doi-asserted-by":"crossref","unstructured":"Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011.","DOI":"10.1038\/ki.2011.33"},{"key":"10.1016\/j.lpm.2011.06.022_bib0385","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.01050207","article-title":"Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis","volume":"2","author":"Cho","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MNH.0b013e32831b7096","article-title":"Relaxin and the progression of kidney disease","volume":"18","author":"Samuel","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.lpm.2011.06.022_bib0395","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/j.1523-1755.2004.00628.x","article-title":"Relaxin-1-deficient mice develop an age-related progression of renal fibrosis","volume":"65","author":"Samuel","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.06.022_bib0400","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.06.022_bib0405","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.lpm.2011.06.022_bib0410","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.lpm.2011.06.022_bib0415","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMoa022287","article-title":"Circulating endothelial progenitor cells, vascular function, and cardiovascular risk","volume":"348","author":"Hill","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0420","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.06.022_bib0425","doi-asserted-by":"crossref","first-page":"F1314","DOI":"10.1152\/ajprenal.90755.2008","article-title":"Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease","volume":"296","author":"Krenning","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.lpm.2011.06.022_bib0430","doi-asserted-by":"crossref","first-page":"e11477","DOI":"10.1371\/journal.pone.0011477","article-title":"Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease\u2013a prospective follow-up study","volume":"5","author":"Lorenzen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2011.06.022_bib0435","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/eurheartj\/ehq254","article-title":"Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans","volume":"32","author":"Thum","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2011.06.022_bib0440","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCULATIONAHA.108.788653","article-title":"Endothelial progenitor cells restore renal function in chronic experimental renovascular disease","volume":"119","author":"Chade","year":"2009","journal-title":"Circulation"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211003824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211003824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:32:10Z","timestamp":1638491530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498211003824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":88,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0755498211003824"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2011.06.022","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}